病毒性心肌炎患者血清钙卫蛋白A4、A8/A9与病情及预后不良的关系

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1106 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨病毒性心肌炎(VMC)患者血清钙卫蛋白A4(S100A4)、钙卫蛋白A8/A9(S100A8/A9)与病情及预后不良的关系。方法选取2020-11至2022-11武警广东总队医院收治的151例VMC患者,根据病情严重程度分为轻症组(87例)与重症组(64例),同期选取90例在该医院体检的志愿者作为健康组,比较三组入院时的基线资料及血清S100A4、S100A8/A9表达水平。对所有VMC患者随访1年,根据是否发生不良事件分为不良预后组和良好预后组。采用多因素logistic回归分析VMC不良预后的影响因素,受试者工作特征(ROC)曲线分析血清S100A4、S100A8/A9对患者不良预后的预测效能。结果轻症和重症组血清S100A4、S100A8/A9水平均高于健康组(P＜0.05),且重症组的血清S100A4、S100A8/A9水平高于轻症组(P＜0.05)。相较于良好预后组,不良预后组的房室传导阻滞占比、心肌肌钙蛋白Ⅰ、肌酸激酶同工酶、血清S100A4、血清S100A8/A9水平升高(P＜0.05),左室射血分数值降低(P＜0.05)。房室传导阻滞(OR=1.850,95%CI:1.369~2.511)、心肌肌钙蛋白Ⅰ升高(OR=1.738,95%CI:1.285~2.306)、肌酸激酶同工酶升高(OR=1.677,95%CI:1.213~2.127)、S100A4升高(OR=1.409,95%CI:1.021~1.869)、S100A8/A9升高(OR=1.493,95%CI:1.115~1.936)是VMC不良预后的危险因素,左室射血分数升高(OR=0.627,95%CI:0.558~0.815)是保护因素(P＜0.05)。ROC曲线结果显示,血清S100A4、S100A8/A9预测VMC不良预后的AUC分别为0.675、0.719。血清S100A4、S100A8/A9联合预测VMC不良预后的AUC为0.784,大于S100A4或S100A8/A9单独检测。结论血清S100A4、S100A8/A9高表达与VMC患者病情加重及不良预后的发生有关,两指标联合检测可提升对患者不良预后的预测效果。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	孙敏伊
	黄燕
	林更映

关键词 ：病毒性心肌炎, 钙卫蛋白A4, 钙卫蛋白A8/A9, 预后, 预测价值

Abstract：Objective To investigate the relationship between serum calprotectin A4 (S100A4), calprotectin A8/A9 (S100A8/A9) and disease condition and poor prognosis in patients with viral myocarditis (VMC). Methods A total of 151 VMC patients admitted to Guangdong Provincial Corps Hospital of Chinese People's Armed Police Force from November 2020 to November 2022 were divided into a mild group (87 cases) and a severe group (64 cases) according to the severity of the disease. During the same period, 90 healthy volunteers who underwent physical examination in the same hospital were selected as a healthy group. The baseline data and serum S100A4 and S100A8/A9 expression levels in the three groups at admission were compared. All VMC patients were followed up for 1 year, and divided into poor prognosis group and good prognosis group according to the occurrence of adverse events. The influencing factors affecting the poor prognosis of VMC were analyzed by multivariate Logistic analysis, the predictive efficacy of serum S100A4 and S100A8/A9 on the poor prognosis of patients was analyzed by receiver operating characteristic (ROC) curve. Results The levels of serum S100A4 and S100A8/A9 in mild and severe groups were higher than those in healthy group (P＜0.05), and the levels of serum S100A4 and S100A8/A9 in severe group were higher than those in mild group (P＜0.05). Compared with the good prognosis group, the poor prognosis group showed an increase in the proportion of atrioventricular block, cardiac troponin I, creatine kinase isoenzyme, serum S100A4, and serum S100A8/A9 levels (P＜0.05), and a decrease in left ventricular ejection fraction (P＜0.05). Atrioventricular block (OR=1.850,95%CI:1.369-2.511), elevated cardiac troponin I (OR=1.738,95%CI:1.285-2.306), elevated creatine kinase isoenzyme (OR=1.677,95%CI:1.213-2.127), elevated S100A4 (OR=1.409,95%CI:1.021-1.869), and elevated S100A8/A9(OR=1.493,95%CI:1.115-1.936) were risk factors for poor prognosis of VMC, while elevated left ventricular ejection fraction (OR=0.627,95%CI:0.558-0.815) was a protective factor (P＜0.05). ROC curve results showed that the AUC of serum S100A4 and S100A8/A9 to predict the poor prognosis of VMC was 0.675 and 0.719, respectively. The AUC of combining serum S100A4 and S100A8/A9 to predict the poor prognosis of VMC was 0.784, which was greater than that of S100A4 or S100A8/A9 alone. Conclusions The high expression of serum S100A4 and S100A8/A9 is related to the aggravation of VMC and the occurrence of poor prognosis in VMC patients. The combined detection of the two indicators can improve the prediction efficiency of poor prognosis in patients.

Key words： viral myocarditis calprotectin A4 calprotectin A8/A9 prognosis predictive value

收稿日期: 2024-08-09

ZTFLH:

R542.2

基金资助:广东省医学科研基金指令性课题项目(C2020009)

作者简介: 孙敏伊,本科学历,主治医师。

引用本文:

孙敏伊, 黄燕, 林更映. 病毒性心肌炎患者血清钙卫蛋白A4、A8/A9与病情及预后不良的关系[J]. 武警医学, 2025, 36(2): 110-114. SUN Minyi, HUANG Yan, LIN Gengying. Relationship between serum calprotectin A4, A8/A9 and disease condition and poor prognosis in patients with viral myocarditis. Med. J. Chin. Peop. Armed Poli. Forc., 2025, 36(2): 110-114.

链接本文:

https://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 https://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2025/V36/I2/110

[1]	Olejniczak M, Schwartz M, Webber E, et al. Viral myocarditis-Incidence, diagnosis and management[J]. J Cardiothorac Vasc Anesth, 2020, 34(6):1591-1601.
[2]	万娇娇. 病毒性心肌炎免疫机制研究进展[J]. 国际儿科学杂志, 2020, 47(1):26-29.
[3]	姚佳丽, 陈颖睿, 蔡林倩,等. S100蛋白家族在心血管疾病中的研究进展[J]. 生命科学, 2022, 34(12):1569-1577.
[4]	叶佳伦, 陈洁琼, 王小山, 等. 急性非ST段抬高型心肌梗死患者血清S100A4、S100A12与PCI术后预后的关系[J]. 现代生物医学进展, 2023, 23(14):2645-2649.
[5]	Wang W, Ma K, Liu J, et al. Ginkgo biloba extract may alleviate viral myocarditis by suppression of S100A4 and MMP-3[J]. J Med Virol, 2019, 91(12):2083-2092.
[6]	吴民涵, 余嘉敏, 袁泉, 等. S100A8/A9在炎症性肺部疾病中的研究进展[J]. 中华航海医学与高气压医学杂志, 2023, 30(5):673-679.
[7]	Wu Y, Li Y, Zhang C, et al. S100a8/a9 released by CD11b+Gr1+ neutrophils activates cardiac fibroblasts to initiate angiotensin II-Induced cardiac inflammation and injury[J]. Hypertension, 2014, 63(6):1241-1250.
[8]	王娟, 张瑜. 血清S100A4、S100A9、P-selectin在心力衰竭患者中的表达及与预后的相关性[J]. 检验医学与临床, 2022, 19(10):1379-1381,1385.
[9]	张军平,吕仕超,王晓玲,等. 成人急性病毒性心肌炎诊断标准评价与建议[C]. //第八次中国中西医结合中青年学术研讨会暨青年工作委员会工作会议论文集. 2010:28-30.
[10]	卢东东, 唐智奇, 杨帆, 等. 病毒性心肌炎患者外周血miR-146b表达水平与病情及不良预后风险的相关性[J]. 山西医科大学学报, 2022, 53(8):998-1003.
[11]	Rezkalla S H, Kloner R A. Viral myocarditis: 1917-2020: from the influenza A to the COVID-19 pandemics[J]. Trends Cardiovasc Med, 2021, 31(3):163-169.
[12]	Zhang Y, Zhou X, Chen S, et al. Immune mechanisms of group B coxsackievirus induced viral myocarditis[J]. Virulence, 2023, 14(1):2180951.
[13]	王丽娜, 马娜, 孙小刚. 血清adropin、miR-217、miR-92a水平与病毒性心肌炎患者病情严重程度及预后关系研究[J]. 中国病原生物学杂志, 2023, 18(2):224-228,237.
[14]	王伟. S100A4蛋白在病毒性心肌炎中的作用及银杏叶提取物的干预作用研究[D]. 长春:吉林大学, 2012.
[15]	王金龙, 吴巧玲, 沈途, 等. 麻醉前叙事医学干预对老年术后认知功能障碍和S100β蛋白的影响[J]. 锦州医科大学学报, 2021, 42(4):57-61.
[16]	李江涛, 张国珺, 严鹏. 大鼠心肌损伤后S100A4的表达变化及其意义[J]. 中西医结合心脑血管病杂志, 2017, 15(3):313-316.
[17]	杨帆, 夏清, 沈晓飞, 等. 血清S100A4水平与急性心肌梗死患者预后相关性分析[J]. 国际检验医学杂志, 2020, 41(4):465-469.
[18]	陈瑞珍,虞莹,石卉,等. S100A4、S100A8/A9和S100A12作为扩张型心肌病生物标记物的应用: CN202210897101.8[P]. 2022-10-25.
[19]	王西强, 刘成峰, 刘平, 等. B淋巴细胞调控炎症细胞聚集促进血管紧张素Ⅱ/苯肾上腺素诱导的心肌肥厚[J]. 西安交通大学学报(医学版), 2022, 43(5):671-677.
[20]	Ma L P, Haugen E, Ikemoto M, et al. S100A8/A9 complex as a new biomarker in prediction of mortality in elderly patients with severe heart failure[J]. Int J Cardiol, 2012, 155(1):26-32.
[21]	Sreejit G, Abdel-Latif A, Athmanathan B, et al. Neutrophil-Derived S100A8/A9 amplify granulopoiesis after myocardial infarction[J]. Circulation, 2020, 141(13):1080-1094.
[22]	Müller I, Vogl T, Kühl U, et al. Serum alarmin S100A8/S100A9 levels and its potential role as biomarker in myocarditis[J]. ESC Heart Fail, 2020, 7(4):1442-1451.
[23]	Li Y, Chen B, Yang X, et al. S100a8/a9 signaling causes mitochondrial dysfunction and cardiomyocyte death in response to ischemic/reperfusion injury[J]. Circulation, 2019, 140(9):751-764.
[24]	Kovacic M, Mitrovic-Ajtic O, Beleslin-Cokic B, et al. TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms[J]. Cell Oncol (Dordr), 2018, 41(5):541-553.